Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
Status:
Completed
Trial end date:
2021-08-28
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of AMG 596 monotherapy or in combination with AMG 404 in Subjects with
Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant
III (EGFRvIII).
This is a first in human (FIH), open-label, sequential-dose-escalation study in subjects with
EGFRvIII-positive glioblastoma or malignant glioma. This study will enroll 2 groups of
subjects according to disease stage, recurrent disease (Group 1) and maintenance treatment
after SoC in newly diagnosed disease (Group 2).